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what we know currently about Mg it presents a very different picture to that seen for chlamydial infection.
-The manuscript received two reviews at STI but the other reviewer had declined to make the review public.
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 Comments to the Author Many thanks for giving me the opportunity to look through the manuscript. I have made a number of suggestions that I hope you will find useful in your revision.
4 Introduction -This appears to contain quite a few different strains of thought. I suggest that you concentrate on providing information that is directly relevant to supporting the aim of the study presented here and justifying why yet another clinical service based study of positivity is required.
Response: We have restructured the introduction in response to your advice.
5 Methods -a full description of the datasets, their characteristics, biases and the clincial services from which they were taken should be given. This is required as the NCSP data could come from a variety of low risk settings. The potential problem of duplication between the datasets should also be addressed. The authors also need to justify why they included children between the ages of 9 and 15. In view of the results from this group I would be inclined to drop the lowere age group from the analysis.
Response: We have addressed the comment about datasets etc. in the methods section on page 7 and have restricted our analysis to those aged 15 years and above in response to comment 2 by reviewer 2 on age of sample.
6 Discussion -the Discussion needs to be restructured to clearly state the key findings, biases and how these relate to the literature. The authors could then speculate on the likely public health importance of Mg and the information gap that exists between current knowledge and an effective intervention strategies. Given what we know currently about Mg it presents a very different picture to that seen for chlamydial infection.
Response: we have restructured the discussion in response to comments by both reviewers 1 and 2.
VERSION 2 -REVIEW
REVIEWER

Dr Ian Simms
Public Health England REVIEW RETURNED 11-Nov-2013
GENERAL COMMENTS
I have previously reviewed the manuscript for Sexually Transmiitted Infections. The authors have revised the manuscript well but one problem remains. This is concerned with the use of the phrase 'prevalence ...... in the general population'. The NCSP is not a general population sample and therefore it is inaccurate to infer that the NCSP dataset is the same as a general population sample. I would avoid the use of prevalence as this is potentially misleading.
The manuscript has been revised well but one problem remains. This is concerned with the use of the phrase 'prevalence ...... in the general population'. The NCSP is not a general population sample and therefore it is inaccurate to infer that the NCSP dataset is the same as a general population sample. I would avoid the use of prevalence as this is potentially misleading. No statistics are presented on this in the results but I note that the 95% CI for prevalences overlap so assume that the difference was not significant. I find this result difficult to explain as the majority of studies in women find CT more common than MG . 716 women were tested -study duration is surely not relevant its the number tested which is important when considering random variation. CT screening is certainly a possibility which could explain this esp as our recent paper on CT serology suggests CT screening may be having some effect at the population level. But this as you state is speculation (Horner et al PLoS ONE. 2013; 8(8) :e72001) Page 19 lines 22-27: I would quote the Angarius 2013 paper as well. Do you not also mean that azithromycin 1grm has been associated with development of MG macrolide resistance in some studies predominantly symptomatic men.(see above) If 9% of women are indeed co-infected there is a risk that azithromycin 1 grm for treatment of CT may inadvertently by promoting macrolide antimcrobial resistance in MG. This requires further study before firm conclusions can be drawn but I believe is a valid cause for concern. Population based studies have previously shown co-infection in <5% you should discuss this on page 17 line 18-20 I have previously reviewed the manuscript for Sexually Transmiitted Infections. The authors have revised the manuscript well but one problem remains. This is concerned with the use of the phrase 'prevalence ...... in the general population'. The NCSP is not a general population sample and therefore it is inaccurate to infer that the NCSP dataset is the same as a general population sample. I would avoid the use of prevalence as this is potentially misleading.
REVIEWER
